



ANNOUNCEMENT
SUMMARY OF THE MINUTES OF THE ANNUAL GENERAL MEETING OF SHAREHOLDERS FOR 2024
FINANCIAL YEAR PT INDOFARMA Tbk

Hereby, the Board of Directors of PT Indofarma Tbk (the "Company"), announces the Summary of Minutes of the Annual General Meeting of Shareholders for the 2024 Financial Year of the Company ("Meeting") which held on:

- A. Day/Date : **Wednesday, June 25, 2025**
Time : 17.00 – 19.05 WIB
Venue : Indonesia Health Learning Institute (IHLI) – Bio Farma Group
Jl. Cipinang Cempedak I Nomor 36, Jakarta Timur, 13340
- B. Notification of Agenda, Announcement and Invitation for the Meeting have been carried out consecutively in accordance with Article 23 paragraph (3) and paragraph (8) of the Company's Articles of Association and Article 12 and Article 20 paragraph (1) of the Financial Services Authority Regulation Number 15/POJK.04/2020 concerning the Plan and Implementation of General Meetings of Shareholders of Public Companies (hereinafter referred to as "POJK No.15/2020"), namely as follows:

NOTIFICATION OF AGENDA The meeting has been carried out by sending a Company Letter to the Financial Services Authority (hereinafter abbreviated as "OJK") on April 8, 2025 Number 0501/DIR/IV/2025 regarding Notification of the Plan to Hold the Annual General Meeting of Shareholders of PT INDOFARMA Tbk, Company Letter dated April 28, 2025 Number 0583/DIR/IV/2025 regarding Request for Changes to the Schedule for Holding the Annual General Meeting of Shareholders for the 2024 Financial Year ("AGMS") of PT Indofarma Tbk, and the Company's Letter dated June 2, 2025 Number 0753/DIR/VI/2025 regarding Notification of the Agenda of the Annual GMS for the Fiscal Year 2024 of PT Indofarma Tbk.

ANNOUNCEMENT to the Company's Shareholders regarding the plan to hold the Meeting has been made by uploading an advertisement on the Electronic General Meeting System website of the Indonesian Central Securities Depository - hereinafter abbreviated as "eASY.KSEI" (<https://www.akses.ksei.co.id>) on April 15, 2025 which was then revised on April 28, 2025 regarding Changes to the Meeting Schedule.

The SUMMONS to the Company's Shareholders to attend the Meeting has been made by placing an advertisement on the eASY.KSEI website (<https://www.akses.ksei.co.id>), the Indonesia Stock Exchange website - hereinafter abbreviated as "BEI" (<https://idx.co.id>) and the Company's website (<https://www.indofarma.id>), on June 03, 2025.

The Company also uploaded the Meeting Agenda Materials on the Company's website (<https://www.indofarma.id>) on June 05, 2025

- C. There are no additional proposals for Meeting Agendas from the Company's Shareholders until the deadline as stipulated in Article 23 paragraph (6) letter a of the Company's Articles of Association, namely until 7 (seven) days before the date of the Meeting Invitation which was announced on May 27, 2025.
- D. The meeting was attended by all members of the Board of Commissioners and members of the Board of Directors and Shareholders of the Company, namely:

BOARD OF COMMISSIONERS

Independent Commissioner : Mr. TEDDY WIBISANA;

Acting President Commissioner/
Commissioner : Mr. DIDI AGUS MINTADI.

BOARD OF DIRECTORS

Acting President Director/
Operational Director : Mr. ANDI PRAZOS.

as well as Shareholders and proxies of Shareholders who were present physically or electronically through eASY.KSEI who all own 2,925,939,900 shares including Series A Dwiwarna shares or constitute 94.4074656% of the total number of shares with valid voting rights that have been issued by the Company up to the day of the Meeting, namely 3,099,267,500 shares consisting of:

- 1 Series A Dwiwarna share; and
- 3,099,267,499 Series B shares

with due observance of the Company's Shareholders List as of June 2, 2025 until 16:00 Western Indonesia Time.

- E. The meeting was chaired by the Company's Commissioner, Mr. Dr. DIDI AGUS MINTADI based on the letter of the Board of Commissioners dated June 3, 2025 Number S-21/DK-INAF/VI/2025.

F. The Meeting was held with the following Agenda:

1. Approval of the Annual Report and Ratification of the Company's Consolidated Financial Statements, Approval of the Board of Commissioners' Supervisory Task Report and Ratification of the Financial Statements of the Micro and Small Business Funding Program (PUMK) for the 2024 Financial Year, as well as Granting of Full Settlement and Release of Liability (volledig acquit et de charge) to the Board of Directors for the Company's Management Actions and the Board of Commissioners for the Company's Supervisory Actions that have been carried out during the 2024 Financial Year.
2. Approval of the Use of the Company's Net Profit for the 2024 Financial Year.
3. Determination of Salaries/Honorariums including Facilities and Allowances for the 2025 Financial Year, as well as Tantiem/Performance Incentives/Special Incentives for Performance in 2024 for the Company's Board of Directors and Board of Commissioners.

4. Approval of the Appointment of a Public Accountant and/or Public Accounting Firm (KAP) to Audit the Company's Consolidated Financial Statements for the 2025 Financial Year and the Financial Statements of the Micro and Small Business Funding Program (PUMK) for the 2025 Financial Year.
5. Changes to the Company's Management.

G. In the Meeting, the presentation of the Company's general condition was delivered by the Chairperson of the Meeting, namely Mr. Dr. DIDI AGUS MINTADI.

In each Agenda of the Meeting, the opportunity was given to the Company's shareholders and proxies of shareholders who were present physically or electronically to submit questions and/or opinions. In the First, Third, Fourth, and Fifth Agendas of the Meeting, there were no shareholders and proxies of shareholders of the Company who were present physically or electronically who submitted questions and/or opinions. In the Second Agenda of the Meeting, there was 1 (one) Shareholder who submitted a question electronically.

H. That the decision-making mechanism in the Meeting is carried out through deliberation to reach consensus in accordance with Article 40 with due regard to Article 28 of POJK No. 15/2020. In the event that deliberation for consensus is not reached, then the decision is taken through voting. The voting mechanism is carried out openly calculated from the votes legally cast from the Meeting and through eASY.KSEI.

That in the Meeting a decision has been taken as stated in the deed "Minutes of the Second Annual General Meeting of Shareholders for the 2024 Financial Year of PT INDONESIA FARMA Tbk abbreviated as PT INDOFARMA Tbk" dated 25 June 2025 Number 29 whose minutes of the deed were made by Notary **Utiek Rochmuliati Abdurachman, SH., MLI., MKn.** which in essence are as follows:

In the First Agenda of the Meeting:

Of all shares with valid voting rights present and/or represented either physically or electronically at the Meeting, none voted Disagree; 425,907,700 shares or 14.5562696% voted Abstain; while the rest, 2,500,032,200 shares or 85.4437304% including 1 (one) Series A Dwiwarna share voted Agree.

In accordance with the provisions of the Meeting Rules of Procedure, Shareholders who do not vote (abstain) are deemed to have cast the same vote as the majority vote of Shareholders who cast votes.

Thus, the Meeting unanimously based on deliberation to reach a consensus, namely 2,925,939,900 shares or 100% of the total number of votes cast at the Meeting decided:

1. Approve the Company's Annual Report including the Board of Commissioners' Supervisory Task Report for the Financial Year ending on December 31, 2024.

2. Ratify:

- a) **The Company's Consolidated Financial Statements for the Financial Year 2024 ending on December 31, 2024 which have been audited by the Public Accounting Firm HELIANTONO and Partners in accordance with its report Number 00386/2.0459/AU.1/04/0916-1/1/IV/2025 dated April 17, 2025 with the opinion "Fair with Exceptions" in connection with the failure to obtain sufficient and appropriate audit evidence on the recoverable value of consolidated fixed assets**

- and inventories in which there are assets of a subsidiary, namely PT IGM, which on February 10, 2025 was declared bankrupt with all its legal consequences by the Central Jakarta District Court;
- b) Financial Report of the Micro and Small Business Funding Program for the 2024 Financial Year ending on December 31, 2024 which is part of the Social and Environmental Responsibility Report as audited by the Public Accounting Firm HELIANTONO and Partners according to its report Number 00683/2.0459/AU.2/04/0916-1/1/IV/2025 dated April 17, 2025 with the opinion "fair in all material respects",
3. The Board of Directors and Board of Commissioners are requested to fully resolve the matters that caused the recording of losses in the Company's Consolidated Financial Statements for the 2024 Financial Year and to consistently carry out their duties and functions carefully and prudently to optimize all resources owned by PT Indofarma Tbk in order to fully resolve the restructuring of PT Indofarma Tbk, in order to maintain the continuity of the Company's business.
 4. With the approval of the Company's Annual Report including the Board of Commissioners' Supervisory Task Report, and the ratification of the Company's Consolidated Financial Statements and the Financial Statements of the Micro and Small Business Funding Program (PUMK), for the 2024 Financial Year ending on December 31, 2024, the General Meeting of Shareholders grants release and discharge (acquit et de charge) to all members of the Board of Directors for their management actions and to all members of the Board of Commissioners for their supervisory actions carried out during the 2024 Financial Year ending on December 31, 2024, except for the cause of the opinion "Fair with Exceptions", as long as such actions do not constitute a criminal act and/or violate the provisions of applicable laws and legal procedures, and are reflected in the Company's report books.

In the Second Agenda of the Meeting:

Of all shares with valid voting rights present and/or represented either physically or electronically at the Meeting, none voted Disagree; of 425,907,700 shares or 14.5562696% voted Abstain; while the rest, 2,500,032,200 shares or 85.4437304% including 1 (one) Series A Dwiwarna share voted Agree.

In accordance with the provisions of the Meeting Rules of Procedure, Shareholders who do not vote (abstain) are deemed to have cast the same vote as the majority of Shareholders who cast votes.

Thus, the Meeting unanimously based on deliberation for consensus, namely 2,925,939,900 shares or 100% of the total number of votes cast at the Meeting decided:

Approved that there is no determination of the Use of the Company's Net Profit because the Company experienced a net loss in the 2024 Financial Year.

In the Third Agenda of the Meeting:

Of all shares with valid voting rights present and/or represented both physically and electronically at the Meeting, 0 shares or 0% voted Disagree; 425,907,700 shares or 14.5562696% voted Abstain; while the rest, 2,500,032,200 shares or 85.4437304% including 1 (one) Series A Dwiwarna share voted Agree.

In accordance with the provisions in the Meeting Rules of Procedure, Shareholders who do not vote (abstain) are deemed to have cast the same vote as the majority vote of Shareholders who cast votes.

Thus, the Meeting unanimously based on deliberation to reach a consensus, namely 2,925,939,900 shares or 100% of the total number of votes cast at the Meeting decided:

Approve the Determination of Tantiem/Performance Incentives/Special Incentives for the 2024 Financial Year, Salaries for the Board of Directors and Honorariums for the Board of Commissioners along with other facilities and allowances for the Year 2025, will be determined separately by the Series A Dwiwarna Shareholders.

In the Fourth Agenda of the Meeting:

Of all shares with valid voting rights present and/or represented either physically or electronically at the Meeting, 0 shares or 0% voted Disagree; 425,907,700 shares or 14.5562696% voted Abstain; while the rest, amounting to 2,500,032,200 shares or 85.4437304% including 1 (one) Series A Dwiwarna share voted Agree.

In accordance with the provisions of the Meeting Rules of Procedure, Shareholders who do not vote (abstain) are deemed to have cast the same vote as the majority vote of Shareholders who cast votes.

Thus, the Meeting unanimously based on deliberation for consensus, namely 2,925,939,900 shares or 100% of the total number of votes issued at the Meeting decided:

- 1. Granting authority to the Board of Commissioners after first obtaining written approval from the Most Series B Shareholders to appoint a Public Accounting Firm to carry out an audit of the Company's Consolidated Financial Statements and the Financial Statements for the Implementation of the Micro and Small Business Funding Program (PUMK) for the 2025 Financial Year, including other reports in 2025.**
- 2. Delegating authority to the Company's Board of Commissioners to determine the amount of fees for audit services of the Public Accounting Firm that has been approved in decision number 1) above and the addition of the scope of work required and other requirements that are reasonable for the Public Accounting Firm.**
- 3. Delegating authority to the Board of Commissioners after first obtaining written approval from the Most Series B Shareholders to determine:**
 - a. A replacement Public Accounting Firm if the appointed Public Accounting Firm cannot continue or carry out its duties for any reason; and**
 - b. Conditions, requirements for appointment and honorarium of the replacement Public Accounting Firm.**

In the Fifth Agenda of the Meeting:

Of all shares with valid voting rights present and/or represented either physically or electronically at the Meeting, none voted Disagree; 425,907,700 shares or 14.5562696% voted Abstain; while the remainder, 2,500,032,200 shares or 85.4437304% including 1 (one) Series A Dwiwarna share voted Agree.

In accordance with the provisions of the Meeting Rules of Procedure, Shareholders who do not vote (abstain) are deemed to have cast the same vote as the majority vote of Shareholders who cast votes.

Thus, the Meeting unanimously based on deliberation to reach a consensus, namely 2,925,939,900 shares or 100% of the total number of votes cast in the Meeting decided:

- 1. Approve the honorable dismissal of the members of the Board of Directors and Board of Commissioners of PT INDOFARMA Tbk, as follows:**
 - a. Mrs. YELIANDRIANI as President Director;**
 - b. Mr. TEDDY WIBISANA as Independent Commissioner;**
 - c. Mr. Dr. DIDI AGUS MINTADI as Commissioner.****effective as of the closing of this year's Annual GMS, with gratitude for the contribution of energy and thoughts given during their respective terms as members of the Board of Directors and Board of Commissioners of PT INDOFARMA Tbk.**
- 2. Approve the appointment of the names below as members of the Board of Directors and Board of Commissioners of PT INDOFARMA Tbk, as follows:**
 - a. Mr. SAHAT SIHOMBING as President Director;**
 - b. Mr. Dr. DIDI AGUS MINTADI as Commissioner for the second term.**
- 3. The term of office of the members of the Board of Directors and Board of Commissioners appointed as referred to in number 2, in accordance with the provisions of the Company's Articles of Association, taking into account the laws and regulations in the Capital Market sector and without prejudice to the right of the GMS to dismiss at any time.**
- 4. With the dismissal and appointment of members of the Board of Directors and Board of Commissioners as referred to in numbers 1 and 2 above, the composition of the membership of the Board of Commissioners and Board of Directors of PT INDOFARMA Tbk is as follows:**

BOARD OF COMMISSIONERS

President Commissioner : -
Commissioner : Mr. DIDI AGUS MINTADI.

BOARD OF DIRECTORS

President Director : Mr. SAHAT SIHOMBING;
Operational Director : Mr. ANDI PRAZOS

Jakarta, June 30, 2025
Board of Directors of the Company